-
- Jennifer C. Rodrigues
- Department of Medicine, University of Toronto and Division of Nephrology, University Health Network, Toronto, Ontario, Canada;
-
- Mark Haas
- Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California; and
-
- Heather N. Reich
- Department of Medicine, University of Toronto and Division of Nephrology, University Health Network, Toronto, Ontario, Canada;
説明
<jats:p>IgA nephropathy (IgAN) is a leading cause of CKD and renal failure. Recent international collaborative efforts have led to important discoveries that have improved our understanding of some of the key steps involved in the immunopathogenesis of IgAN. Furthermore, establishment of multicenter networks has contributed to rigorous design and execution of clinical trials that have provided important insights regarding immunotherapy in IgAN. In this article, we review emerging developments in clinical and translational IgAN research and describe how these novel findings will influence future strategies to improve the outcome of patients with IgAN.</jats:p>
収録刊行物
-
- Clinical Journal of the American Society of Nephrology
-
Clinical Journal of the American Society of Nephrology 12 (4), 677-686, 2017-02-03
Ovid Technologies (Wolters Kluwer Health)
